Pricing drugs, selling hype and how we got here in the first place
May 15, 2018 - 15:46
Radio and PodcastLive Radio & Podcasts
Science & Medicine
Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup
Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the future of Valeant Pharmaceuticals.
Related Episodes
Continue listening to more episodes from FierceBiotech Radio.
